Voloridge Investment Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-19,654
| Closed | -$1.06M | – | 1027 |
|
|
2025
Q4 | $1.06M | Sell |
19,654
-700,299
| -97% | -$33.7M | ﹤0.01% | 996 |
|
|
2025
Q3 | $32.5M | Buy |
719,953
+586,720
| +440% | +$27.4M | 0.11% | 226 |
|
|
2025
Q2 | $6.17M | Buy |
+133,233
| New | +$6.54M | 0.02% | 699 |
|
|
2024
Q4 | – | Sell |
-289,735
| Closed | -$15M | – | 1186 |
|
|
2024
Q3 | $15M | Sell |
289,735
-2,570,878
| -90% | -$121M | 0.05% | 457 |
|
|
2024
Q2 | $119M | Buy |
2,860,613
+144,469
| +5% | +$6.46M | 0.44% | 44 |
|
|
2024
Q1 | $147M | Sell |
2,716,144
-2,274,027
| -46% | -$116M | 0.54% | 34 |
|
|
2023
Q4 | $256M | Buy |
4,990,171
+2,664,152
| +115% | +$140M | 1.01% | 5 |
|
|
2023
Q3 | $135M | Buy |
2,326,019
+451,621
| +24% | +$27.7M | 0.67% | 14 |
|
|
2023
Q2 | $120M | Buy |
1,874,398
+1,753,484
| +1,450% | +$118M | 0.57% | 22 |
|
|
2023
Q1 | $8.38M | Sell |
120,914
-194,105
| -62% | -$13.7M | 0.04% | 503 |
|
|
2022
Q4 | $22.7M | Buy |
315,019
+46,580
| +17% | +$3.51M | 0.13% | 232 |
|
|
2022
Q3 | $19.1M | Sell |
268,439
-1,431,291
| -84% | -$104M | 0.1% | 264 |
|
|
2022
Q2 | $131M | Buy |
+1,699,730
| New | +$129M | 0.68% | 6 |
|
|
2021
Q3 | – | Sell |
-749,804
| Closed | -$50.1M | – | 1654 |
|
|
2021
Q2 | $50.1M | Buy |
749,804
+294,875
| +65% | +$19.2M | 0.35% | 41 |
|
|
2021
Q1 | $28.7M | Buy |
454,929
+195,378
| +75% | +$12.2M | 0.21% | 129 |
|
|
2020
Q4 | $16.1M | Buy |
259,551
+157,315
| +154% | +$9.67M | 0.14% | 182 |
|
|
2020
Q3 | $6.16M | Sell |
102,236
-444,033
| -81% | -$26.7M | 0.05% | 387 |
|
|
2020
Q2 | $32.1M | Buy |
+546,269
| New | +$32.7M | 0.37% | 52 |
|
|
2019
Q4 | – | Sell |
-356,662
| Closed | -$18.1M | – | 1093 |
|
|
2019
Q3 | $18.1M | Buy |
+356,662
| New | +$16.8M | 0.31% | 48 |
|
|
2019
Q2 | – | Sell |
-739,674
| Closed | -$35.3M | – | 772 |
|
|
2019
Q1 | $35.3M | Buy |
+739,674
| New | +$36.8M | 1.06% | 11 |
|
|
2018
Q4 | – | Sell |
-3,235
| Closed | -$201K | – | 409 |
|
|
2018
Q3 | $201K | Buy |
+3,235
| New | +$192K | ﹤0.01% | 281 |
|
|
2018
Q1 | – | Sell |
-94,036
| Closed | -$5.76M | – | 503 |
|
|
2017
Q4 | $5.76M | Sell |
94,036
-13,868
| -13% | -$867K | 0.13% | 180 |
|
|
2017
Q3 | $6.88M | Sell |
107,904
-280,313
| -72% | -$16.4M | 0.15% | 134 |
|
|
2017
Q2 | $21.6M | Buy |
+388,217
| New | +$21.1M | 0.54% | 47 |
|
|
2016
Q3 | – | Sell |
-942,911
| Closed | -$69.4M | – | 231 |
|
|
2016
Q2 | $69.4M | Buy |
942,911
+689,384
| +272% | +$48.7M | 1.98% | 8 |
|
|
2016
Q1 | $16.2M | Buy |
+253,527
| New | +$16M | 0.38% | 61 |
|
|
2015
Q2 | – | Sell |
-613,757
| Closed | -$39.6M | – | 305 |
|
|
2015
Q1 | $39.6M | Buy |
+613,757
| New | +$38.4M | 1.91% | 10 |
|
|
2014
Q3 | – | Sell |
-21,191
| Closed | -$1.03M | – | 102 |
|
|
2014
Q2 | $1.03M | Buy |
+21,191
| New | +$1.04M | 0.1% | 71 |
|
Other funds holding BMY
VCM
VPM
Voloridge Investment Management's BMY Position: Q1 2026 in Review
Voloridge Investment Management sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 19,654 shares — an estimated $1.06M sold.
Voloridge Investment Management first reported a position in BMY in Q2 2014 and held it in 28 quarters. The position peaked at $256M in Q4 2023. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Voloridge Investment Management reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
- Voloridge Investment Management sold 19,654 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.06M.
- Voloridge Investment Management first reported a position in Bristol-Myers Squibb in Q2 2014 and held it in 28 quarters.
- Voloridge Investment Management's Bristol-Myers Squibb position peaked at $256M in Q4 2023.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.